Moderna Vaccine Can 100% Prevent Severe Cases Of COVID-19

Moderna, while investigating the data from its Phase III trial, has discovered that its vaccine could 100% prevent COVID-19 severe cases.

The trial involved 30,000 participants. 15,000 received the actual vaccine while the remaining were given the placebo.

Among these, 196 were infected with the novel coronavirus. Only 11 received the vaccine. From the placebo group, 30 got severe cases of COVID-19. None of the 15 volunteers who got the vaccine became seriously ill.

Moderna states that these findings remain consistent across different demographics including gender, age, and ethnicity. The vaccine has shown to have minimal side effects including fatigue, pain at the injection spot, and headache.

The company has announced that it will submit the vaccine for regulatory approval while seeking authorization for emergency use after its Phase III trials are completed. The effectiveness of the vaccine is said to be 94.1% against the virus.

The vaccine of Moderna uses mRNA in the recipient’s body to create an immune response. If the Moderna vaccine receives approval, it will be the first one.

If everything goes as planned, Moderna plans to ship 20 million doses of its vaccine by the end of this year to vaccinate 10 million people in the US. And throughout 2021, its goal is to manufacture about 500 million to 1 billion doses.

After Pfizer-BioNTech, Moderna has become the second vaccine to submit for regulatory approval.

>>> Pfizer and BioNTech SE COVID-19 Vaccine Approved In The UK, Expected To Make 50 Million Doses